Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “hold” rating reaffirmed by research analysts at Canaccord Genuity in a report issued on Tuesday. They currently have a $16.00 target price on the specialty pharmaceutical company’s stock. Canaccord Genuity’s target price points to a potential upside of 11.27% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Stifel Nicolaus restated a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a report on Friday, June 30th. BidaskClub upgraded Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a report on Thursday, June 29th. Guggenheim started coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They issued a “buy” rating and a $18.00 price objective on the stock. Jefferies Group LLC restated a “buy” rating and issued a $18.00 price objective on shares of Valeant Pharmaceuticals International in a report on Friday, July 14th. Finally, Cantor Fitzgerald set a $23.00 price objective on Valeant Pharmaceuticals International and gave the stock a “buy” rating in a report on Friday, July 28th. Five investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $17.67.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 14.38 on Tuesday. The firm’s 50-day moving average is $14.00 and its 200 day moving average is $13.38. Valeant Pharmaceuticals International has a 1-year low of $8.31 and a 1-year high of $24.48. The stock’s market capitalization is $5.01 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The firm had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. During the same quarter in the prior year, the company posted ($0.88) earnings per share. The firm’s revenue was down 7.7% on a year-over-year basis. On average, analysts expect that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/valeant-pharmaceuticals-international-inc-vrx-stock-rating-reaffirmed-by-canaccord-genuity/1608933.html.

In other news, Director Schutter Richard U. De bought 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, with a total value of $143,300.00. Following the completion of the transaction, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.87% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Gruss & Co. Inc. bought a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at $104,000. Harbor Advisors LLC bought a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at $110,000. PNC Financial Services Group Inc. lifted its holdings in shares of Valeant Pharmaceuticals International by 33.7% during the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after acquiring an additional 2,763 shares during the period. Baird Financial Group Inc. bought a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at $127,000. Finally, OLD Mutual Customised Solutions Proprietary Ltd. lifted its holdings in shares of Valeant Pharmaceuticals International by 357.7% during the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 11,900 shares of the specialty pharmaceutical company’s stock valued at $131,000 after acquiring an additional 9,300 shares during the period. 50.48% of the stock is owned by institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.